Evidence map›Paper›PMID 39196658›Full record

ArticleMolecular biology of the cell2024

mDia2 is an important mediator of MRTF-A-dependent regulation of breast cancer cell migration.

Ian Eder, Virginia Yu, Jacob Antonello, Fangyuan Chen, David Gau, Pooja Chawla, Marion Joy, Peter C Lucas, David Boone, Adrian V Lee and 1 more

Abstract read
In one paragraph

Article in Molecular biology of the cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Ian EderBioengineering, University of Pittsburgh, PA 15219.
Virginia YuBioengineering, University of Pittsburgh, PA 15219.
Jacob AntonelloBioengineering, University of Pittsburgh, PA 15219.
Fangyuan ChenSchool of Medicine, University of Pittsburgh, PA 15261.
David GauBioengineering, University of Pittsburgh, PA 15219.
Pooja ChawlaBioengineering, University of Pittsburgh, PA 15219.
Marion JoyHillman Cancer Center, University of Pittsburgh, PA 15232.
Peter C LucasLaboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905.
David BooneBiomedical Informatics, University of Pittsburgh, PA 15206.
Adrian V LeePharmacology, University of Pittsburgh, PA 15213.
Partha RoyBioengineering, University of Pittsburgh, PA 15219.ORCID 0000-0002-4946-8531

Funding

NRSA Training CoreTL1TR001858 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI RADOMSKI, THOMAS, RUBIO, DORIS M · 2016 to 2025
$11.1M
Cellular Approaches to Tissue Engineering/RegenerationT32EB001026 · NIBIB · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUNCAN, ANDREW W, MONGA, SATDARSHAN SINGH · 2003 to 2024
$5.5M
Training Program in Imaging Sciences in Translational Cardiovascular ResearchT32HL129964 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Flordeliza S Villanueva · 2016 to 2026
$4.7M
Profilin biology in breast cancerR01CA248873 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROY, PARTHA · 2021 to 2025
$1.8M
Transcriptional Regulation of Dormancy and Emergence in Breast CancerR01CA271095 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARTHA ROY · 2023 to 2026
$1.5M
Discovery of Cell-based Chemical Probes Targeting Aberrant Angiogenesis in the EyeR21EY032632 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HURYN, DONNA M, KOES, DAVID RYAN · 2022 to 2023
$426k
Profilin as a Novel Target for Vascular Normalization in Renal CancerK99CA267180 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GAU, DAVID MARTIN · 2022 to 2023
$252k
NCATS NIH HHS TL1 TR001858NCI NIH HHS K99 CA267180NCI NIH HHS R01 CA248873NCI NIH HHS R01 CA271095NEI NIH HHS R21 EY032632NHLBI NIH HHS T32 HL129964NIBIB NIH HHS T32 EB001026
6 · The paper itself

Abstract

Dysregulated actin cytoskeleton gives rise to aberrant cell motility and metastatic spread of tumor cells. This study evaluates the effect of overexpression of wild-type versus functional mutants of MRTF-A on migration and invasion of breast cancer (BC) cells. Our studies indicate that SRF's interaction is critical for MRTF-A-induced promotion of both two-dimensional and three-dimensional cell migration, while the SAP-domain function is important selectively for three-dimensional cell migration. Increased MRTF-A activity is associated with more effective membrane protrusion, a phenotype that is attributed predominantly to SRF's interaction with MRTF. We demonstrate formin-family protein mDia2 as an important mediator of MRTF-stimulated actin polymerization at the leading edge and cell migration. Multiplexed quantitative immunohistochemistry and transcriptome analyses of clinical BC specimens further demonstrate a positive correlation between nuclear localization of MRTF with malignant traits of cancer cells and enrichment of MRTF-SRF gene signature in pair-matched distant metastases versus primary tumors. In conclusion, this study establishes a novel mechanism of MRTF-dependent regulation of cell migration and provides evidence for the association between MRTF activity and increased malignancy in human BC, justifying future development of specific small molecule inhibitors of the MRTF-SRF transcriptional complex as potential therapeutic agents in BC.

Indexed as

Breast NeoplasmsCell MovementForminsTrans-ActivatorsActin CytoskeletonActinsAdaptor Proteins, Signal TransducingCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansSerum Response FactorActinsAdaptor Proteins, Signal TransducingDIAPH2 protein, humanForminsMRTFA protein, humanSerum Response FactorTrans-Activators

Identifiers

PMID39196658
PMCPMC11481706

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.